Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial

ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats

(2013) Yasuo Ochi et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Renal safety in patients treated with bisphosphonates for osteoporosis: A review

(2013) Paul D Miller et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Effect of the Cathepsin K Inhibitor ONO-5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study

(2013) Klaus Engelke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study

(2013) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females

(2013) Chihiro Hasegawa et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers

(2012) S. Aubrey Stoch et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

(2012) Bente Langdahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Benefits and Risks of Bisphosphonate Therapy for Osteoporosis

(2012) Sundeep Khosla et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study

(2011) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO-5334, in an Ascending Multiple-Dose, Phase 1 Study

(2011) Shinichi Nagase et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib

(2011) Thomas M. Rnger et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials

(2010) M. A. Karsdal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy

(2009) A. Rogers et al.   BONE

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

(2009) S A Stoch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

The influence of circadian rhythms on the kinetics of drugs in humans

(2008) Massimo Baraldo   Expert Opinion on Drug Metabolism & Toxicology

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH